# Type 2 Diabetes Exemplar: A Remote Care Service for North West London

Study · id `cardio:ct-nct04731142` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04731142](<https://clinicaltrials.gov/study/NCT04731142>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04731142

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 235 participants.

## Technical summary

Registry record NCT04731142. Non-randomized; no masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2022-06-30 (actual). Results posted on 2024-02-20.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 235 participants (enrolled count; ClinicalTrials.gov record NCT04731142, source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)
- Started: 2021-06-01 (actual) (ClinicalTrials.gov record NCT04731142, source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)
- Primary completion: 2022-06-30 (actual) (ClinicalTrials.gov record NCT04731142, source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)
- Completion: 2022-10-31 (actual) (ClinicalTrials.gov record NCT04731142, source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)
- Results first posted: 2024-02-20 (ClinicalTrials.gov record NCT04731142, source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT04731142, source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04731142-2024-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Type 2 Diabetes Exemplar: A Remote Care Service for North West London
- Acronym: T2DEx
- Condition: Type 2 Diabetes Mellitus
- Intervention (Device): Huma
- Intervention (Behavioral): Video group consultations
- Intervention (Behavioral): KNOW Diabetes
- Intervention (Other): Standard of care
- Lead sponsor: Imperial College London
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Huma
- Collaborator class: INDUSTRY
- Collaborator: North West London Collaboration of CCGs (NWL CCGs)
- Collaborator class: OTHER
- Collaborator: Imperial College Health Partners (ICHP)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Imperial College London (`cardio:org-imperial-college-london`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 3a6ddbbf8349b21534eaebca440ddb7616e3ef8469ab55ab7959feedcc77f4ba
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
